This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kotler, M. Articles by Volsky, D. J. Search for Related Content PubMed PubMed Citation Articles by Kotler, M. Articles by Volsky, D. J.

 Previous Article  |  Next Article 

J. Virol., Aug 1997, 5774-5781, Vol 71, No. 8
Copyright © 1997, American Society for Microbiology

Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro

M Kotler, M Simm, YS Zhao, P Sova, W Chao, SF Ohnona, R Roller, C Krachmarov, MJ Potash and DJ Volsky
Department of Molecular Genetics, Hadassah Medical School, Hebrew University, Jerusalem, Israel.

Human immunodeficiency virus type 1 (HIV-1) Vif is required for productive infection of T lymphocytes and macrophages. Virions produced in the absence of Vif have abnormal core morphology and those produced in primary T cells carry immature core proteins and low levels of mature capsid (M. Simm, M. Shahabuddin, W. Chao, J. S. Allan, and D. J. Volsky, J. Virol. 69:4582-4586, 1995). To investigate whether Vif influences the activity of HIV-1 protease (PR), the viral enzyme which is responsible for processing Gag and Gag-Pol precursor polyproteins into mature virion components, we transformed bacteria to inducibly express truncated Gag-Pol fusion proteins and Vif. We examined the cleavage of polyproteins consisting of matrix to PR (Gag-PR), capsid to PR (CA-PR), and p6Pol to PR (p6Pol-PR) and evaluated HIV-1 protein processing at specific sites by Western blotting using antibodies against matrix, capsid, and PR proteins. We found that Vif modulates HIV-1 PR activity in bacteria mainly by preventing the release of mature MA and CA from Gag-PR, CA from CA-PR, and p6Pol from p6Pol-PR, with other cleavages being less affected. Using subconstructs of Vif, we mapped this activity to the N-terminal half of the molecule, thus identifying a new functional domain of Vif. Kinetic study of p6Pol-PR autocatalysis in the presence or absence of Vif revealed that Vif and N'Vif reduce the rate of PR-mediated proteolysis of this substrate. In an assay of in vitro proteolysis of a synthetic peptide substrate by purified recombinant PR we found that recombinant Vif and the N- terminal half of the molecule specifically inhibit PR activity at a molar ratio of the N-terminal half of Vif to PR of about 1. These results suggest a mechanism and site of action of Vif in HIV-1 replication and demonstrate novel regulation of a lentivirus PR by an autologous viral protein acting in trans.

This article has been cited by other articles:

• Henriet, S., Sinck, L., Bec, G., Gorelick, R. J., Marquet, R., Paillart, J.-C. (2007). Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res 35: 5141-5153 [Abstract] [Full Text]  
• Gaddis, N. C., Chertova, E., Sheehy, A. M., Henderson, L. E., Malim, M. H. (2003). Comprehensive Investigation of the Molecular Defect in vif-Deficient Human Immunodeficiency Virus Type 1 Virions. J. Virol. 77: 5810-5820 [Abstract] [Full Text]  
• Baraz, L., Hutoran, M., Blumenzweig, I., Katzenellenbogen, M., Friedler, A., Gilon, C., Steinitz, M., Kotler, M. (2002). Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region. J. Gen. Virol. 83: 2225-2230 [Abstract] [Full Text]  
• Khan, M. A., Akari, H., Kao, S., Aberham, C., Davis, D., Buckler-White, A., Strebel, K. (2002). Intravirion Processing of the Human Immunodeficiency Virus Type 1 Vif Protein by the Viral Protease May Be Correlated with Vif Function. J. Virol. 76: 9112-9123 [Abstract] [Full Text]  
• Bardy, M., Gay, B., Pebernard, S., Chazal, N., Courcoul, M., Vigne, R., Decroly, E., Boulanger, P. (2001). Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing. J. Gen. Virol. 82: 2719-2733 [Abstract] [Full Text]  
• Sova, P., Volsky, D. J., Wang, L., Chao, W. (2001). Vif Is Largely Absent from Human Immunodeficiency Virus Type 1 Mature Virions and Associates Mainly with Viral Particles Containing Unprocessed Gag. J. Virol. 75: 5504-5517 [Abstract] [Full Text]  
• Henzler, T., Harmache, A., Herrmann, H., Spring, H., Suzan, M., Audoly, G., Panek, T., Bosch, V. (2001). Fully functional, naturally occurring and C-terminally truncated variant human immunodeficiency virus (HIV) Vif does not bind to HIV Gag but influences intermediate filament structure. J. Gen. Virol. 82: 561-573 [Abstract] [Full Text]  
• Öhagen, A., Gabuzda, D. (2000). Role of Vif in Stability of the Human Immunodeficiency Virus Type 1 Core. J. Virol. 74: 11055-11066 [Abstract] [Full Text]  
• Davis, D. A., Yusa, K., Gillim, L. A., Newcomb, F. M., Mitsuya, H., Yarchoan, R. (1999). Conserved Cysteines of the Human Immunodeficiency Virus Type 1 Protease Are Involved in Regulation of Polyprotein Processing and Viral Maturation of Immature Virions. J. Virol. 73: 1156-1164 [Abstract] [Full Text]  
• Potash, M. J., Bentsman, G., Muir, T., Krachmarov, C., Sova, P., Volsky, D. J. (1998). Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif. Proc. Natl. Acad. Sci. USA 95: 13865-13868 [Abstract] [Full Text]